Drug search by name

Vincasar PFS and Hepatic dysfunction

Result of checking the interaction of drug Vincasar PFS and disease Hepatic dysfunction for safety when used together.

Check result:

Vincasar PFS <> Hepatic dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Vincristine is primarily metabolized by the liver. The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated. Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials. Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity. Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function. Close clinical monitoring of hepatic function is recommended.

References:

"Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
Jackson DV, Jr Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978): 101-7
Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982): 215-9

Vincasar PFS

Generic Name: vincristine

Brand Name: Oncovin, Vincasar PFS

Synonyms: n.a.

What is Vincasar PFS?